Randomized double-blind, placebo-controlled study of oral gabapentin for prevention of neuropathy in patients receiving paclitaxel

Randomized double-blind, placebo-controlled study of oral gabapentin for prevention of neuropathy in patients receiving paclitaxel

Abstract Background Peripheral neuropathy is a common dose-limiting side effect of paclitaxel. To date, there is no effective strategy to prevent paclitaxel-induced peripheral neuropathy. A recent small phase II study demonstrated the potential role of oral gabapentin in this setting. This phase III...

Full description

Bibliographic Details
Main Authors: Praful Pandey, Akash Kumar, Deepam Pushpam, Sachin Khurana, Prabhat Singh Malik, Ajay Gogia, Elavarasi Arunmozhimaran, Mamta Bhushan Singh, Dinu Santha Chandran, Atul Batra
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Trials
Subjects:
Paclitaxel
Neuropathy
Gabapentin
Breast cancer
Ovarian cancer
Prevention
Online Access:https://doi.org/10.1186/s13063-023-07126-1

Internet

https://doi.org/10.1186/s13063-023-07126-1

Similar Items